Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Imunon Inc IMNN

Healthcare Biotechnology
Imunon, Inc. is a clinical-stage biotechnology company. The Company is focused on advancing a portfolio of treatments that harness the body’s natural mechanisms across an array of human diseases, constituting a differentiating approach from conventional therapies. The Company is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the... see more

Recent & Breaking News (NDAQ:IMNN)

IMUNON's Chief Science Officer to Present at the 3rd International Vaccines Congress

GlobeNewswire October 23, 2023

IMUNON CEO Dr. Corinne Le Goff to Participate in a Panel Discussion on Pandemic Preparedness at the United Nations

GlobeNewswire October 19, 2023

IMUNON Announces First Patient enrolled in Phase 1/2 Clinical Trial of IMNN-001 in Combination with bevacizumab in Advanced Ovarian Cancer

GlobeNewswire October 18, 2023

IMUNON Appoints Dr. Patrick Ott to its Scientific Advisory Board

GlobeNewswire October 6, 2023

IMUNON Reports Interim Progression-Free Survival and Overall Survival Data in Phase 1/2 OVATION 2 Study in Advanced Ovarian Cancer

GlobeNewswire September 28, 2023

IMUNON Releases Enterprise Video Highlighting the Company's Mission, Vision, Values, Breakthroughs and Technologies

GlobeNewswire September 26, 2023

IMUNON Reminds Investors of its Virtual R&D Day Tomorrow at 4:00 p.m. ET

GlobeNewswire September 13, 2023

IMUNON to Host Virtual R&D Day on September 14th Beginning at 4:00 p.m. ET

GlobeNewswire September 7, 2023

IMUNON to Participate in the H.C. Wainwright Global Investment Conference

GlobeNewswire September 5, 2023

IMUNON Enters into CRADA for Preclinical Studies of PlaCCine Modality in Preventive Vaccines Against Lassa Virus

GlobeNewswire August 24, 2023

IMUNON Expands Scientific Advisory Board with the Addition of Dr. Sachet Shukla

GlobeNewswire August 14, 2023

IMUNON Reports Second Quarter 2023 Financial Results and Provides Business Update

GlobeNewswire August 10, 2023

Preclinical Data Showing Strong Immunogenicity and Protection with IMUNON's PlaCCine DNA-Based Vaccines Modality Available Online on bioRxiv

GlobeNewswire August 7, 2023

IMUNON to Hold Second Quarter 2023 Financial Results and Business Update Conference Call on Thursday, August 10, 2023

GlobeNewswire August 3, 2023

IMUNON Unveils New Manufacturing Capabilities at Huntsville's HudsonAlpha Biotech Campus

GlobeNewswire June 27, 2023

Imunon Reports Inducement Grants under NASDQ Listing Rule 5646(c)(4)

GlobeNewswire June 26, 2023

IMUNON CEO to Discuss Company's Novel Non-viral DNA Therapy Option at the Mass General Brigham World Medical Innovation Forum 2023

GlobeNewswire June 12, 2023

IMUNON's CEO Presents Business Overview to Investors and Senior Biopharmaceutical Professionals at the BIO 2023 International Convention

GlobeNewswire June 8, 2023

IMUNON Presents PlaCCine Preclinical Data at the 2023 Viruses and Cells - Gordon Research Conference

GlobeNewswire May 30, 2023

IMUNON Reports First Quarter 2023 Financial Results and Provides Business Update

GlobeNewswire May 11, 2023